Type 2 diabetes: increased mortality with low HbA1c.
Five-year follow-up data from the Accord trial once again confirm that it is better to target an HbAlc level between 7% and 7.5% rather than a lower value, in patients with type 2 diabetes and a high risk of cardiovascular events.
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000401:mortality; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013997:Time Factors
D006442:Glycated Hemoglobin; D000960:Hypolipidemic Agents